Nomura Holdings Inc. raised its position in Zoetis Inc (NYSE:ZTS) by 6.3% during the second quarter, Holdings Channel.com reports. The institutional investor owned 339,900 shares of the company’s stock after purchasing an additional 20,052 shares during the quarter. Nomura Holdings Inc.’s holdings in Zoetis were worth $38,578,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in ZTS. FMR LLC boosted its position in Zoetis by 12.2% in the first quarter. FMR LLC now owns 8,127,931 shares of the company’s stock valued at $818,239,000 after buying an additional 882,183 shares in the last quarter. BlackRock Inc. lifted its holdings in Zoetis by 2.2% in the first quarter. BlackRock Inc. now owns 37,486,408 shares of the company’s stock valued at $3,773,759,000 after buying an additional 795,558 shares during the period. American Century Companies Inc. lifted its holdings in Zoetis by 12.8% in the first quarter. American Century Companies Inc. now owns 4,539,546 shares of the company’s stock valued at $456,996,000 after buying an additional 513,924 shares during the period. Close Asset Management Ltd acquired a new position in Zoetis in the first quarter valued at approximately $47,140,000. Finally, Bank of New York Mellon Corp lifted its holdings in Zoetis by 9.5% in the second quarter. Bank of New York Mellon Corp now owns 4,420,261 shares of the company’s stock valued at $501,654,000 after buying an additional 383,799 shares during the period. Hedge funds and other institutional investors own 90.09% of the company’s stock.

In other Zoetis news, insider Clinton A. Jr. Lewis sold 6,123 shares of the company’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $113.09, for a total value of $692,450.07. Following the completion of the sale, the insider now owns 46,812 shares of the company’s stock, valued at $5,293,969.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Kristin C. Peck sold 11,500 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $123.22, for a total transaction of $1,417,030.00. Following the completion of the sale, the executive vice president now directly owns 48,877 shares of the company’s stock, valued at approximately $6,022,623.94. The disclosure for this sale can be found here. Insiders sold 34,332 shares of company stock valued at $4,163,091 in the last ninety days. Insiders own 0.29% of the company’s stock.

NYSE:ZTS traded up $0.83 during trading hours on Friday, hitting $125.10. The stock had a trading volume of 133,736 shares, compared to its average volume of 2,059,244. Zoetis Inc has a one year low of $78.90 and a one year high of $130.08. The company has a debt-to-equity ratio of 2.74, a quick ratio of 2.87 and a current ratio of 4.17. The company has a market cap of $59.97 billion, a price-to-earnings ratio of 39.98, a P/E/G ratio of 3.09 and a beta of 0.87. The business’s 50 day moving average is $123.64 and its 200-day moving average is $109.75.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 6th. The company reported $0.90 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.82 by $0.08. Zoetis had a net margin of 22.74% and a return on equity of 72.86%. The firm had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.51 billion. During the same quarter in the prior year, the firm earned $0.77 earnings per share. The business’s quarterly revenue was up 9.3% on a year-over-year basis. On average, sell-side analysts anticipate that Zoetis Inc will post 3.57 EPS for the current fiscal year.

Several brokerages recently weighed in on ZTS. Barclays increased their price objective on shares of Zoetis from $120.00 to $135.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Credit Suisse Group restated a “buy” rating and issued a $130.00 price objective on shares of Zoetis in a report on Wednesday, September 11th. Bank of America lowered shares of Zoetis from a “buy” rating to a “neutral” rating and increased their price objective for the company from $111.00 to $120.00 in a report on Monday, July 1st. They noted that the move was a valuation call. Goldman Sachs Group began coverage on shares of Zoetis in a report on Monday, September 9th. They issued a “conviction-buy” rating and a $145.00 price objective on the stock. Finally, Craig Hallum increased their price objective on shares of Zoetis from $132.00 to $138.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Seven investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. Zoetis currently has a consensus rating of “Buy” and an average target price of $120.94.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

See Also: What are the benefits of buying treasury bonds?

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.